47 related articles for article (PubMed ID: 9276358)
1. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.
Sartor CI; Strawderman MH; Lin XH; Kish KE; McLaughlin PW; Sandler HM
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):941-7. PubMed ID: 9276358
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.
Pendleton JM; Tan WW; Anai S; Chang M; Hou W; Shiverick KT; Rosser CJ
BMC Cancer; 2008 May; 8():132. PubMed ID: 18471323
[TBL] [Abstract][Full Text] [Related]
3. A diet, physical activity, and stress reduction intervention in men with rising prostate-specific antigen after treatment for prostate cancer.
Hébert JR; Hurley TG; Harmon BE; Heiney S; Hebert CJ; Steck SE
Cancer Epidemiol; 2012 Apr; 36(2):e128-36. PubMed ID: 22018935
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.
Pound CR; Brawer MK; Partin AW
Rev Urol; 2001; 3(2):72-84. PubMed ID: 16985694
[TBL] [Abstract][Full Text] [Related]
5. The effective management of biochemical recurrence in patients with prostate cancer.
McLeod DG
Rev Urol; 2005; 7 Suppl 5(Suppl 5):S29-36. PubMed ID: 16985881
[TBL] [Abstract][Full Text] [Related]
6. Post-therapeutic squamous cell transformation of a metastatic prostate adenocarcinoma with comparison of molecular profiles: a case report and review of the literature.
Li P; Haines GK; Si Q; Baskovich B
Int J Clin Exp Pathol; 2024; 17(3):78-82. PubMed ID: 38577694
[TBL] [Abstract][Full Text] [Related]
7. Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort.
Benedetti E; Chetnik K; Flynn T; Barbieri CE; Scherr DS; Loda M; Krumsiek J
Sci Data; 2023 Nov; 10(1):830. PubMed ID: 38007532
[TBL] [Abstract][Full Text] [Related]
8. MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.
Ménard C; Navarro-Domenech I; Liu ZA; Joseph L; Barkati M; Berlin A; Delouya G; Taussky D; Beauchemin MC; Nicolas B; Kadoury S; Rink A; Raman S; Sundaramurthy A; Weersink R; Beliveau-Nadeau D; Helou J; Chung P
Front Oncol; 2022; 12():971344. PubMed ID: 36091157
[TBL] [Abstract][Full Text] [Related]
9. Association between prostate-specific antigen change over time and prostate cancer recurrence risk: A joint model.
Ali Mohammadpour R; Alizadeh A; Barzegar MR; Akbarzadeh Pasha A
Caspian J Intern Med; 2020 May; 11(3):324-328. PubMed ID: 32874441
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.
Mertan FV; Greer MD; Borofsky S; Kabakus IM; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
Top Magn Reson Imaging; 2016 Jun; 25(3):139-47. PubMed ID: 27187164
[TBL] [Abstract][Full Text] [Related]
11. Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?
Arcangeli S; Agolli L; Donato V
Rep Pract Oncol Radiother; 2015; 20(6):425-9. PubMed ID: 26696782
[TBL] [Abstract][Full Text] [Related]
12. Decision-making Processes among Prostate Cancer Survivors with Rising PSA Levels: Results from a Qualitative Analysis.
Shen MJ; Nelson CJ; Peters E; Slovin SF; Hall SJ; Hall M; Herrera PC; Leventhal EA; Leventhal H; Diefenbach MA
Med Decis Making; 2015 May; 35(4):477-86. PubMed ID: 25385751
[TBL] [Abstract][Full Text] [Related]
13. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.
Ahmed KA; Davis BJ; Mynderse LA; Slezak JM; Bergstralh EJ; Wilson TM; Choo CR
Radiat Oncol; 2014 Jul; 9():171. PubMed ID: 25074478
[TBL] [Abstract][Full Text] [Related]
14. Multi-Parametric MRI-Directed Focal Salvage Permanent Interstitial Brachytherapy for Locally Recurrent Adenocarcinoma of the Prostate: A Novel Approach.
Wallace T; Avital I; Stojadinovic A; Brücher BL; Cote E; Yu J
J Cancer; 2013; 4(2):146-51. PubMed ID: 23412660
[TBL] [Abstract][Full Text] [Related]
15. Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial.
Steigler A; Denham JW; Lamb DS; Spry NA; Joseph D; Matthews J; Atkinson C; Turner S; North J; Christie D; Tai KH; Wynne C
Prostate Cancer; 2012; 2012():814724. PubMed ID: 23320177
[TBL] [Abstract][Full Text] [Related]
16. Semiparametric Stochastic Modeling of the Rate Function in Longitudinal Studies.
Zhu B; Taylor JM; Song PX
J Am Stat Assoc; 2011 Dec; 106(496):1485-1495. PubMed ID: 22423170
[TBL] [Abstract][Full Text] [Related]
17. MR imaging of treated prostate cancer.
Vargas HA; Wassberg C; Akin O; Hricak H
Radiology; 2012 Jan; 262(1):26-42. PubMed ID: 22190655
[TBL] [Abstract][Full Text] [Related]
18. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
Smith MR; Cook R; Lee KA; Nelson JB
Cancer; 2011 May; 117(10):2077-85. PubMed ID: 21523719
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram.
Hugen CM; Polcari AJ; Quek ML; Garza RP; Fitzgerald MP; Flanigan RC
World J Urol; 2010 Dec; 28(6):741-4. PubMed ID: 20449749
[TBL] [Abstract][Full Text] [Related]
20. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Scattoni V; Garcia Parra R; Briganti A; Gianolli L; Montorsi F; Messa C
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
